Pfizer and Astellas Report Follow-up Data from P-III (KEYNOTE-A39/EV-302) Trial of Padcev + Keytruda for Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
Shots:
- Pfizer & Astellas have reported follow-up data from P-III (KEYNOTE-A39/EV-302) trial assessing Padcev + Keytruda vs Pt-based CT in previously untreated la/mUC pts (n=886)
- The 12mos. follow up study (mFU: 29.1mos.) showed reduced risk of death by 49% & decrease in PFS by 52% (mPFS: 12.5 vs 6.3mos.) with improved mOS (33.8 vs 15.9mos.), where OS benefit was observed in all prespecified groups (incl. cisplatin eligible & ineligible pts)
- Additionally, an exploratory analysis in evaluable pts showed higher cORR (67.5% vs. 44.2%), with mDoR of 23.3 vs 7mos., plus cCR was achieved in 30.4% vs 14.5% pts, where median duration of cCR was not reached for enfortumab regimen vs 15.2mos. for CT; Data to be presented at ASCO GU
Ref: Businesswire | Image: Pfizer & Astellas
Related News:- Pfizer Reveals Data from P-III (BREAKWATER) trial of Braftovi Regimen in Patients with Metastatic Colorectal Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
